Sponsors (9)
The bill improves data, surveillance, and produces policy recommendations to better identify and respond to cholangiocarcinoma risk among Vietnam‑era veterans while temporarily preserving one month of pension protections, but it adds modest taxpayer costs and risks incomplete case counts and delayed benefit action if Congress does not act on recommendations.
Vietnam‑era veterans will get improved cholangiocarcinoma surveillance and analysis (incidence vs. U.S. population plus age/gender/race/ethnicity/location breakdowns), enabling VA and health systems to target screening, monitoring, and outreach to high‑risk groups.
Congress and VA will receive evidence‑based recommendations within a year after study completion to inform administrative or legislative responses to any identified veteran health needs.
Veterans who receive the affected Title 38 pension payments retain eligibility/payment protections for one additional month (through Dec 31, 2031), avoiding short‑term lapses in benefits.
Veterans may not see timely benefit changes: study findings could raise expectations for immediate benefit expansions, but Congress may not act on recommendations, leaving veterans waiting for relief.
Registry‑based analyses may miss veterans not captured in VA or CDC registries, undercounting cases and misrepresenting incidence — which could skew policy, screening priorities, and resource allocation.
The mandated study, ongoing reporting, and the one‑month extension impose modest administrative costs and some additional federal spending borne by taxpayers and VA/CDC resources.
Based on analysis of 3 sections of legislative text.
Requires VA, with CDC, to study cholangiocarcinoma incidence in Vietnam-theater veterans using cancer registries and report findings to Congress; delays a pension-related statutory date by one month.
Requires the Department of Veterans Affairs, working with the CDC, to begin an epidemiological study within 120 days to measure rates and demographic patterns of cholangiocarcinoma (a bile duct cancer) among veterans who served in the Vietnam theater compared with the U.S. population, using VA and state cancer registries. The VA must report study findings to Congress within one year after study completion, provide follow-up reports as determined, and continue tracking cholangiocarcinoma prevalence in covered Vietnam-era veterans through the VA Central Cancer Registry. Also delays by one month a statutory date in title 38 related to a limitation on certain pension payments (changing November 30, 2031 to December 31, 2031).
Official title: To direct the Secretary of Veterans Affairs to study and report on the prevalence of cholangiocarcinoma in veterans who served in the Vietnam theater of operations during the Vietnam era, and for other purposes.
Introduced January 21, 2025 by Nicholas LaLota · Last progress April 8, 2025